SEARCH

Current Edition

Crohn's disease

Theravance to lay off 75% of employees alongside larger restructuring

The restructuring at Theravance comes just weeks after one of the company’s more closely watched drugs failed a key test. Called izencitinib, the drug is …

Continue Reading →
autoimmune diseases

With new results, J&J’s $1B gamble on a targeted inflammation drug faces long odds

Izencitinib is a JAK inhibitor, a type of drug that blocks an enzyme involved in inflammation. The drug class is well-established, having already produced multiple …

Continue Reading →